CD274 and neoplasm: Finally, evolving changes in the tumor microenvironment, including increased infiltration of effector T cells, pro-inflammatory cytokines, and PD-L1 expression, may mediate both therapeutic response and subsequent immune toxicity, possibly in a time-dependent manner, supporting the notion that delayed irAE onset may reflect an evolving immune equilibrium favorable to survival [27,28].